Outlook Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Outlook Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Outlook Therapeutics Inc
Rating: 0.61391675
Author: Trendlyne DVM scores

about

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...

0.54 -0.02 (-3.57%)

82.12% Fall from 52W High

2.5M

XNAS Volume

XNAS 14 Jan, 2026 4:14 PM (EST)

Not Eligible

Expensive Valuation

4.7 / 100

Technically Bearish

19.9 / 100

1Yr Price target upside is 896%

4 analysts

Outlook Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Outlook Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...

82.12% Fall from 52W High

SWOT Analysis

Outlook Therapeutics Inc Live Price Chart